REG - Genflow Biosciences - New Research Agreement

Genflow BiosciencesAnnouncement

27/06/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220627:nRSa2590Qa&default-theme=true

RNS Number : 2590Q  Genflow Biosciences PLC  27 June 2022

PRESS RELEASE

27 June 2022

Genflow Biosciences Plc

 

("Genflow" or "the Company")

 

Research Agreement Signed with Magnitude Biosciences Limited

 

Genflow (LSE: GENF) is pleased to announce it has entered into a research
agreement with Magnitude Biosciences Limited ("Magnitude"), a UK-based,
specialist biotechnology research organisation that supports drug discovery
and product development.

Founded in 2018 as a Durham University spin out, Magnitude provides an
automated service to identify health-span extending drugs faster and more cost
effectively than current approaches.

Magnitude leverages Artificial Intelligence and uses nematode worms, called C.
elegans, for in-vivo testing in aging research, to accelerate early,
pre-clinical drug development for biotech and pharmaceutical firms. Its
sophisticated 'Magnitude Biosciences Healthspan technology' enables it to
monitor large numbers of C. elegans under multiple conditions and effectively
assess the impact of compounds on health and longevity.

Magnitude is led by Dr Weinkove who has over 20 years' experience in C.
elegans research, deep biological expertise across multiple research areas and
a rich track record in the longevity field. Furthermore, he was appointed as
the new Chair of the British Society for Research on Ageing in January this
year.

The collaboration will accelerate Genflow's future therapeutic developments
and puts the Company on track to carry out its research and pre-clinical drug
discovery.

Magnitude will commence generating transgenic strains of C. elegans on behalf
of Genflow to test the effect of the expression of human variants of the
Sirtuin-6 gene mutation found in centenarians (people aged more than 100 years
old) on in-vivo function during aging by analysing C. elegans for
age-dependent movement decline.

Genflow is a UK-based biotechnology company focused on longevity and the
development of therapies to counteract the effects of aging and diseases
associated with advanced age.

Dr Eric Leire, Founder and CEO of Genflow, said: "We are very excited with
this collaboration which gives us the opportunity to work with a company that
has tremendous experience in longevity and has a uniquely skilled team.
Through this collaboration, Genflow's future therapeutic developments will be
accelerated by Magnitude's innovative technology which has the capacity to
significantly expedite product development, supported by sophisticated machine
monitoring."

For further information please contact:

 Genflow Biosciences Plc
 Dr Eric Leire                       via Tancredi +44 203 434 2330

 Chief Executive
 Clear Capital Markets Ltd
 Corporate Broker                    +44 203 869 6086

 Jonathan Critchley                  +44 203 897 0981

 Keith Swann
 Tancredi Intelligent Communication

 Media Relations
 Salamander Davoudi                  +44 7957 549 906

 Helen Humphrey                      +44 7449 226 720

 Benedetta Negri da Oleggio          +44 7838 029 970

                                     genflowbio@tancredigroup.com

 

About Genflow

Genflow is a UK-based biotechnology company established in 2020. The Company
is developing gene therapies designed to target the aging process and to
reduce and delay the incidence of age-related diseases. This will be done
through novel therapeutics targeting aging in humans by using adeno associated
virus ("AAV") vectors to deliver copies of the Sirtuin-6 ("SIRT6") gene
variant that is found in centenarians into cells.

Its mission is to increase understanding of the factors that control and
impact lifespan. Genflow researches, develops, and commercialises therapeutic
solutions to lengthen health span, the amount of time we live in good health,
creating biological interventions that enable longer and healthier lives.
Genflow is dedicated to the development and commercialisation of novel
therapeutics targeting aging in dogs and humans. By treating aging, Genflow
can contribute to a decrease in healthcare costs and lessen the emotional and
societal burden that comes with an aging population.

To learn more visit www.genflowbio.com (http://www.genflowbio.com)

About Magnitude

Magnitude is a UK-based specialist Contract Research Organisation (CRO) who
help industry and academia progress their research projects via its team of
expert scientists, C. elegans services and unique automated imaging
technology.

Magnitude was founded in 2018 by a team of the world's leading C. elegans and
automated imaging experts who shared the vision of bringing the benefits of
this unique research approach to industry, helping to play their part in
accelerating the development of new drug therapies and other research advances
to improve human and environmental health. Magnitude helps biotechnology
companies, pharmaceutical companies, health products companies, manufacturing
and anyone else undertaking Research and Development (R&D) who can benefit
from its C. elegans health span technology and expertise. Magnitude's key
research areas include early preclinical drug discovery projects, microbiome,
aging, neurodegeneration and neurodegenerative diseases, environmental
toxicity, reproductive toxicity, and C. elegans transgenics.

To learn more visit https://magnitudebiosciences.com/
(https://magnitudebiosciences.com/)

 

 

-Ends-

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGRBKOBQPBKKNAB